|
Daré Bioscience, Inc. (DARE) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Daré Bioscience, Inc. (DARE) Bundle
Möchten Sie den inneren Wert von Daré Bioscience, Inc. beurteilen? Unser DARE DCF-Taschenrechner integriert reale Daten mit umfassenden Anpassungsfunktionen, sodass Sie Ihre Prognosen verfeinern und Ihre Investitionsauswahl verbessern können.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | 10.0 | 2.8 | 2.3 | 1.9 | 1.5 | 1.3 | 1.0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | -71.92 | -17.98 | -17.98 | -17.98 | -17.98 | -17.98 |
| EBITDA | -14.3 | -27.4 | -39.0 | -31.4 | -30.9 | .5 | .4 | .3 | .3 | .2 |
| EBITDA, % | 100 | 100 | 100 | -313.61 | -1100.53 | 20 | 20 | 20 | 20 | 20 |
| Depreciation | .0 | .0 | .0 | .0 | .0 | 1.4 | 1.1 | .9 | .8 | .6 |
| Depreciation, % | 100 | 100 | 100 | 0.47617 | 1.37 | 60.37 | 60.37 | 60.37 | 60.37 | 60.37 |
| EBIT | -14.3 | -27.4 | -39.1 | -31.4 | -30.9 | .5 | .4 | .3 | .3 | .2 |
| EBIT, % | 100 | 100 | 100 | -314.09 | -1101.89 | 20 | 20 | 20 | 20 | 20 |
| Total Cash | 4.8 | 4.7 | 51.7 | 34.7 | 10.5 | 2.3 | 1.9 | 1.5 | 1.3 | 1.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .6 | .5 | 1.1 | 1.7 | .9 | 1.6 | 1.3 | 1.1 | .9 | .7 |
| Account Receivables, % | 100 | 100 | 100 | 17.03 | 33.81 | 70.17 | 70.17 | 70.17 | 70.17 | 70.17 |
| Inventories | -1,107.5 | -1,852.4 | -2,474.1 | .0 | .0 | 1.4 | 1.1 | .9 | .8 | .6 |
| Inventories, % | 100 | 100 | 100 | 0 | 0 | 60 | 60 | 60 | 60 | 60 |
| Accounts Payable | 1.1 | 1.0 | 2.1 | 2.0 | 3.4 | 1.9 | 1.6 | 1.3 | 1.1 | .9 |
| Accounts Payable, % | 100 | 100 | 100 | 20.28 | 120.57 | 84.06 | 84.06 | 84.06 | 84.06 | 84.06 |
| Capital Expenditure | .0 | .0 | .0 | -.1 | -.6 | -.1 | -.1 | -.1 | -.1 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | -0.63069 | -22.42 | -4.61 | -4.61 | -4.61 | -4.61 | -4.61 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -14.3 | -27.4 | -38.7 | -31.4 | -30.9 | .5 | .4 | .3 | .3 | .2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 1,093.7 | 717.6 | 583.4 | -2,506.2 | -29.4 | -1.8 | 1.6 | 1.3 | 1.1 | .9 |
| WACC, % | 9.89 | 9.89 | 9.89 | 9.89 | 9.89 | 9.89 | 9.89 | 9.89 | 9.89 | 9.89 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 2.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 1 | |||||||||
| Terminal Value | 12 | |||||||||
| Present Terminal Value | 7 | |||||||||
| Enterprise Value | 9 | |||||||||
| Net Debt | -9 | |||||||||
| Equity Value | 18 | |||||||||
| Diluted Shares Outstanding, MM | 7 | |||||||||
| Equity Value Per Share | 2.52 |
What You Will Get
- Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Daré Bioscience, Inc. (DARE) financial data pre-filled to facilitate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically for you.
- Customizable and Professional: A refined Excel model tailored to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, validating strategies, and enhancing efficiency.
Key Features
- Comprehensive DARE Data: Pre-loaded with Daré Bioscience’s historical financials and future growth projections.
- Customizable Assumptions: Modify revenue growth rates, profit margins, discount rates, tax implications, and capital investments.
- Interactive Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on user-defined inputs.
- Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation results.
- Intuitive Interface: Designed for ease of use, catering to both industry professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Daré Bioscience’s pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you tweak assumptions.
- Step 5: Analyze the outputs and use the results for investment decisions related to Daré Bioscience, Inc. (DARE).
Why Choose Daré Bioscience, Inc. (DARE)?
- Innovative Solutions: Pioneering advancements in women's health and reproductive medicine.
- Expert Team: Led by industry veterans with extensive experience in biopharmaceuticals.
- Strong Pipeline: A robust portfolio of product candidates addressing unmet medical needs.
- Commitment to Safety: Rigorous clinical trials ensure the highest standards of patient care.
- Proven Track Record: Consistent progress and transparency in research and development efforts.
Who Should Use This Product?
- Investors: Evaluate Daré Bioscience's (DARE) market potential before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts.
- Startup Founders: Understand how biotech companies like Daré Bioscience are valued in the market.
- Consultants: Provide comprehensive valuation reports to clients in the life sciences sector.
- Students and Educators: Utilize real-time data to learn and teach valuation strategies in biotechnology.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Daré Bioscience historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Daré Bioscience, Inc. (DARE).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.